Segui
daniele santini
daniele santini
professor in general pathology
Email verificata su unicampus.it
Titolo
Citata da
Citata da
Anno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
25552010
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
6942009
Management of cancer pain: ESMO clinical practice guidelines
CI Ripamonti, D Santini, E Maranzano, M Berti, F Roila
Annals of oncology 23, vii139-vii154, 2012
6472012
Tissue invasion and metastasis: Molecular, biological and clinical perspectives
WG Jiang, AJ Sanders, M Katoh, H Ungefroren, F Gieseler, M Prince, ...
Seminars in cancer biology 35, S244-S275, 2015
5602015
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
J Clin oncol 27 (16), 2622-2629, 2009
5032009
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
4672003
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises
F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ...
Cancer treatment reviews 41 (2), 114-121, 2015
4522015
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
3802007
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3572002
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
3252019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ...
Journal for immunotherapy of cancer 7 (1), 1-11, 2019
3202019
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
3022008
Bone health in cancer: ESMO clinical practice guidelines
R Coleman, P Hadji, JJ Body, D Santini, E Chow, E Terpos, S Oudard, ...
Annals of oncology 31 (12), 1650-1663, 2020
2982020
Designing a broad-spectrum integrative approach for cancer prevention and treatment
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...
Seminars in cancer biology 35, S276-S304, 2015
2982015
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
2552008
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
2432020
Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
FR Bertani, P Mozetic, M Fioramonti, M Iuliani, G Ribelli, F Pantano, ...
Scientific reports 7 (1), 8965, 2017
2232017
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, UV Gentilucci, B Vincenzi, A Picardi, F Vasaturo, A La Cesa, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2222003
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
2202007
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85-92, 2010
2172010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20